Impact Factor
3.38
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.26
361 total citations
h5-index
24
h5 depth signal
Cited share
71.1%
81 of 114
Total citations
361
Citation footprint
Metric signal
4.11
External metric anchor
Self-citation
5.3%
19 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
351
United Kingdom
77
Sweden
51
Netherlands
51
Switzerland
48
Citing Fields of Research
Pharmacology & Toxicology
211
Statistical Methods
137
Cancer Drugs
99
Drug Delivery Systems
60
Medical Ethics
51
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,216
Articles tracked across the journal lifetime
Indexed publication set
114
81 cited publications
Last 12 months
66
5.5 publications/month
Open access share
54.5%
36 OA publications in the last year
Leading citing country
United States
351 citing publications
Leading citing field
Pharmacology & Toxicology
211 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v28n1, Feb. 2001-
v28n1, Feb. 2001-
Active Coverage
Research Focus & Classification
Indexed Subjects
Pharmacology & Toxicology
Statistical Methods
Cardiology
Drug Delivery Systems
AI & Machine Learning
Cancer Drugs
Broad Categories
Pharmacology
Statistical Methods
Medical Ethics
Cancer Drugs
Separation Techniques
Pharmacology & Toxicology
Immunotherapy
Musculoskeletal Disorders
MeSH Descriptors
Dose-Response Relationship, Drug
Pharmacokinetics
Pharmacology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s10928-026-10071-6
Open DOI
Population pharmacokinetic–pharmacodynamic modeling and dose selection of GS1-144 based on luteinizing hormone suppression in postmenopausal women
GS1-144 is a novel neurokinin-3 receptor (NK3R) antagonist under development for the treatment of vasomotor symptoms (VMS) associated with menopause. Suppression of luteinizing hormone (LH), a downstream marker of hypothalamic kisspeptin...
02
DOI 10.1007/s10928-026-10067-2
Open DOI
Modified frequency-based sensitivity analysis for oscillatory system models
Global sensitivity analysis (GSA) is a critical and widely used method for evaluating model performance, as it quantifies input variability and uncertainty in both linear and nonlinear systems, with or without parameter interactions. How...
03
DOI 10.1007/s10928-026-10066-3
Open DOI
Evaluation of two model-based Bayesian approaches for vancomycin dosing in general hospitalized patients
Recent guidelines recommend Bayesian forecasting for vancomycin dosing. However, the agreement and predictive performance of different pharmacokinetic models remain unclear in hospitalized patients in general. This study evaluated two mo...
04
DOI 10.1007/s10928-026-10062-7
Open DOI
Prior-informed population pharmacokinetic-pharmacodynamic modeling of dexamethasone in horses
Dexamethasone (DEX) is widely used in equine practice with diverse studies having characterized its pharmacokinetics (PK) and pharmacodynamics (PD) including our published comprehensive meta-analysis. Individual DEX concentrations in pla...
05
DOI 10.1007/s10928-026-10057-4
Open DOI
Formalizing method choice: a data-driven selection of mechanistic models for predicting human heart drug partitioning
We developed a workflow based on a human-derived dataset, aiming to predict the human heart-to-plasma partition coefficient, . The workflow combines established mechanistic tissue-composition models with an AI/ML-based selector that sup...
06
DOI 10.1007/s10928-026-10065-4
Open DOI
Modelling the tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine from early pregnancy to postpartum at steady state
Long-acting cabotegravir and rilpivirine combination (LA-CAB/RPV) is approved for HIV treatment whilst LA-CAB alone is approved for HIV prevention, both in adults. However, individuals who become pregnant might prefer to discontinue it d...
07
DOI 10.1007/s10928-026-10064-5
Open DOI
Evaluation of a model averaging algorithm for model-informed precision dosing in the context of parameter misspecifications
A primary challenge for integrating model-informed precision dosing (MIPD) in clinical settings is selecting the best-fit model for newly presented patients. A model averaging algorithm (MAA) proposed by Uster et al., addresses this by l...
08
DOI 10.1007/s10928-026-10060-9
Open DOI
A systems pharmacology model for paracetamol overdose and treatment
09
DOI 10.1007/s10928-026-10059-2
Open DOI
In silico modeling of methadone-related ion current effects to predict QT interval prolongation
Methadone is commonly associated with QT interval prolongation, which can lead to torsades de pointes. This effect has primarily been attributed to blockade of the delayed rectifier potassium current, I Kr . However, methadone inhibits o...
10
DOI 10.1007/s10928-026-10061-8
Open DOI
Development of an isavuconazole physiologically-based pharmacokinetic model for adult and pediatric populations
Isavuconazonium sulfate is the water-soluble prodrug of the active triazole antifungal agent isavuconazole. Isavuconazonium sulfate is approved for the treatment of invasive aspergillosis and invasive mucormycosis in pediatric and adult ...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.